Compare AGNC Investment Corp (AGNC) vs BridgeBio Pharma Inc (BBIO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AGNC Investment Corp vs BridgeBio Pharma Inc — how do they compare? AGNC Investment Corp trades at $10.9 (market cap $12.74B), while BridgeBio Pharma Inc trades at $83.9 (market cap $16.61B). The key difference: BridgeBio Pharma Inc is the larger of the two by market cap, and AGNC Investment Corp pays a 13.4% dividend while BridgeBio Pharma Inc pays none. Which is the better fit depends on your goals.
| AGNC | BBIO | |
|---|---|---|
Market Cap | $12.74B | $16.61B |
Sector | Financials | Health |
52-Week High | $12.17 | $90.17 |
52-Week Low | $9.46 | $47.29 |
Dividend Yield | 13.4% | — |
Enterprise Value | — | $18.16B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AGNC Investment trades at $10.84, up 2.17% today, with a bullish technical signal and strong earnings beats in Q1 and Q2 2026. The stock offers a high dividend yield, with consistent monthly payouts, and trades at a P/E of 5.39 and P/B of 1.22. Recent news highlights its 13%+ yield and stable dividend history, though analyst consensus is mixed with a Hold majority.
Outlook remains positive due to robust net income margins above 94% and economic returns, but risks include interest rate sensitivity and leveraged mortgage securities. The consensus price target of $11.30 suggests modest upside, supported by institutional interest and earnings momentum, though volatility from macroeconomic factors warrants caution.
BridgeBio Pharma (BBIO) trades at $84.48, up 2.03% with bullish technical signals from moving averages. Despite strong revenue growth from $222M in 2024 to $502M in 2025, the company reports significant losses with a -144.39% net margin. Recent FDA acceptance for encaleret in ADH1 and Attruby's commercial expansion in ATTR-CM provide growth catalysts, though cash flow remains negative at -$111M in 2025.
The stock presents high-risk growth potential with 88% analyst buy ratings and $102.20 consensus target, but faces substantial execution risks from ongoing losses and $1.72B debt load. Success hinges on pipeline approvals and Attruby's market penetration, making it suitable for risk-tolerant investors betting on biotech breakthroughs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AGNC Investment Corp
AGNC Investment Corp is a real estate investment trust that invests in agency residential mortgage-backed securities. The firm's asset portfolio is comprised of residential mortgage pass-through securities and collateralized mortgage obligations for which the principal and interest payments are guaranteed by a U.S. Government-sponsored enterprise, such as the Federal National Mortgage Association and the Federal Home Loan Mortgage Corporation, or by a U.S. Government agency, such as the Government National Mortgage Association. It also invests in other types of mortgage and mortgage-related residential and commercial mortgage-backed securities or other investments in or related to, the housing, mortgage or real estate markets.
Read more on AGNC →About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →
